News

In this interview with Dr. Steven Feldman, the latest findings on tralokinumab-ldrm as an atopic dermatitis treatment were discussed.

Guselkumab effectively cleared the skin of patients with moderate-to-severe plaque psoriasis across all skin tones, with significant improvements observed within the first 16 weeks of treatment.

Findings were presented in an abstract at ACG 2023, highlighting the importance of addressing bowel urgency in patients with ulcerative colitis.

Genentech announced the FDA had approved faricimab-svoa (Vabysmo) for retinal vein occlusion on October 26, 2023, which marks the third ophthalmic indication for the bispecific antibody.

New data from ACG 2023 shows etrasimod-treated patients were able to achieve UC remission, with or without concomitant steroid treatment at baseline.

In this discussion, Dr. Jeff Yu explores the topic of atopic dermatitis treatment news and the upcoming decision by the FDA on tapinarof for this skin disease.

Eli Lilly and Company announced the FDA approval of mirikizumab (Omvoh) for moderately and severely active ulcerative colitis in adults on October 26, 2023.

The number of biosimilars in rheumatology is growing. Test your knowledge of biosimilars with this quiz.

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field.

Patients with moderate to severe scalp psoriasis treated with tildrakizumab exhibited sustained efficacy through week 52, demonstrating the long-term effectiveness and safety profile of this treatment.

In this Fall Clinical Dermatology Conference interview, Dr. Burgess answered several questions related to aesthetic treatments for patients with skin of color, including specific recommendations.

New QUASAR analysis shows patients with intolerance or failed response to advanced therapies nonetheless achieved benefit with guselkumab.

Results presented in a paper at ACG 2023 showed upadacitinib was more effective than ustekinumab for achieving clinical response and endoscopic remission.

Patients in the deucravacitinib group had higher response rates compared with placebo at week 16, regardless of the extent of baseline PASI score or BSA involvement.

In this episode, hosts discuss data from the PROTECT trial, which examined the effects of teplizumab on beta-cell function in patients with newly diagnosed type 1 diabetes.

Patients with scalp and body psoriasis who used nonsteroidal roflumilast foam .3% once daily experienced significant symptom improvement as early as 2 weeks.

Utilizing swept-source OCT, the analysis reports significantly thicker subfoveal choroidal thickness among patients with active disease than those with inactive disease.

Results presented at ACG 2023 demonstrated the viability of the HOMA-IR model for calculating insulin resistance to identify lean NAFLD.

The FDA has accepted Akebia Therapeutics' resubmission of the vadadustat NDA for anemia in chronic kidney disease. PDUFA date is March 27, 2024.

New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks—which correlated with improved quality-of-life scores.

Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.

Results revealed the inner lower and inner left subfields of the better eye were more strongly associated with vision-related quality of life than the worse eye.

An analysis of more than 700 videos on TikTok reveals new insight into the levels and purveyors of misinformation in the most popular ophthalmology content on the platform.

The UCLA hepatologist discusses the current treatment landscape, prospects for improved diagnostics, and the overlap syndrome live from ACG 2023.

New data suggests retinal vein occlusion in individuals under 75 years of age correlates with increased dementia risk, while those older than 75 have a reduced risk.

Volume and frequency of alcohol consumption were associated with a greater risk of visual impairment and blindness among patients with newly diagnosed OAG.

The post-hoc analysis of a phase 3 clinical trial suggests SB15 has comparable clinical efficacy and safety to aflibercept in patients with nAMD.

A multi-target stool RNA test effectively screened individuals age 45 and older for colorectal cancer and advanced adenomas.